

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**Diagnostics Advisory Committee (DAC)**

**Minutes of the Meeting on Wednesday 13 June 2018**

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

**PRESENT:**

**Standing Committee members:**

Dr Mark Kroese – **Chair**  
Ms Liz Adair  
Mr John Bagshaw  
Dr Owen Driskell  
Dr Simon Fleming  
Dr Jim Gray  
Mr John Hitchman  
Professor Christopher Hyde  
Mr Patrick McGinley  
Dr Michael Messenger  
Mrs Alexandria Moseley  
Dr Shelley Rahman Haley  
Dr Simon Richards  
Professor Mark Sculpher  
Professor Matt Stevenson  
Dr Nick Summerton

**Standing Committee apologies:**

Professor Enitan Carrol  
Professor Steve Halligan  
Dr Dermot Neely  
Professor Anthony Wierzbicki

**NICE staff in attendance:**

Mark Campbell, Acting Programme Director – Devices and Diagnostics  
Rebecca Albrow, Senior Technical Adviser, DAP  
Donna Barnes, Project Manager, DAP  
Frances Nixon, (Technical lead) Technical Analyst, DAP  
Christopher Pomfrett, Technical Adviser, MTEP  
Alexandra Sexton, Administrator, DAP

**Observing:**

Clare Harland, Project Manager, CHTE 2020, NICE  
Ann Greenwood, Senior Medical Editor, NICE  
Ian Mather, Resource Impact Assessment, NICE (*morning*)  
Adam Storrow, Resource Impact Assessment, NICE (*afternoon*)  
Katie Wyart, Adoption and Impact, NICE

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chair explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 10 April 2018 committee meeting.

**5. Equality and Diversity**

The Chair reminded the Committee to raise any potential equality issues related to the topic under discussion.

**Assessment of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)**

**External Assessment Group (EAG) representatives: School of Health and Related Research (SchARR), the University of Sheffield:**

Dr Alice Bessey, Research Assistant  
Dr Sue Harnan, Research Fellow  
Dr Katy Cooper, Research Fellow  
Dr Paul Tappenden, Reader

**Specialist Committee members:**

Dr Maria Bramley, Breast Surgeon  
Dr John Graham, Consultant Oncologist  
Linda Pepper, Lay member  
Ursula Van Mann, Lay member

**Specialist Committee members' apologies:**

Dr Deirdre Ryan, Consultant Cellular Pathologist  
Dr Britta Stordal, Consultant Clinical Scientist  
Professor Andrew Wardley, Consultant & MAHSC Professor in Medical Oncology

**PART 1 AND PART 2 (open and closed parts of the meeting)**

**Part 1 – Open session**

The Chair welcomed representatives from Agendia N.V., Genomic Health, Myriad Genetics, and NanoString Technologies.

There were 12 public attendees.

Committee members present had declared relevant interests as below and no further updates to these interests were declared at the meeting:

Liz Adair declared an indirect interest as Roche Diagnostics supply products and equipment to Viapath Services LLP and she is the Quality Director of Viapath Group LLP. This interest was reviewed by the Programme Director and it was agreed that she could participate in the meeting.

Dr Owen Driskell declared an indirect personal interest as his wife works as a Health and Safety professional at AstraZeneca's Macclesfield site. This interest was reviewed by the Programme Director and it was agreed that he could participate in the meeting.

Professor Chris Hyde declared an indirect financial interest as he works for a university which is an evidence contractor for NICE (PenTAG at the University of Exeter). The report for the topic under discussion was not produced by this group. This interest was reviewed by the Programme Director and it was agreed that he could participate in the meeting.

Dr Michael Messenger declared a direct non-financial interest as he is a co-investigator on a recent Myriad Genetics funded health economics evaluation at the University of Leeds, evaluating the impact of an unrelated test, Prolaris for prostate cancer prognosis. As part of this, Myriad Genetics paid for his lunch (<£20) on 3rd October 2017 to discuss the Prolaris project. He also declared an indirect non-financial interest as colleagues within the NIHR MIC in Leeds, for which he is the Deputy Director, are co-investigators on the OPTIMA trial. He also declared a direct non-financial interest as Myriad Genetics had approached him in March 2014 about a potential future evaluation of EndoPredict; he said he would not discuss this with them until the revision of the topic under discussion is complete. He further declared an indirect financial interest as Myriad Genetics, Roche Diagnostics and Genomic Health sponsored the NIHR Leeds In Vitro Diagnostic Launch event in March 2018. These interests were reviewed by the Programme Director and it was agreed that he could participate in the meeting.

Dr Simon Richards declared a financial interest as he is employed as RA Vice President by Abbott who are a direct competitor to Roche Diagnostics. This interest was reviewed by the Programme Director and it was agreed that he could participate in the meeting.

Professor Mark Sculpher declared a direct financial interest as he had received a consultancy fee from Roche Diagnostics for ongoing work unrelated to the products under consideration or breast cancer. This interest was reviewed by the Programme Director and it was agreed that he could participate in the meeting.

Professor Matt Stevenson declared non-financial professional and personal interests as he is the Director of SchARR-TAG who have been allocated to undertake the Diagnostics Assessment Report (DAR) for the topic under discussion. These interests were reviewed by the Programme Director and it was agreed that he could participate in the meeting

Specialist committee members present had declared relevant interests as below and no further updates to these interests were declared at the meeting:

Professor John Graham declared the following direct financial interests:

- He gave an invited presentation in September 2017 on the use of tamoxifen for the prevention of breast cancer to the Medicines and Healthcare products Regulatory Agency and received an honorarium of £200 plus travel expenses.
- He gave an invited lecture in June 2017 at the American Society of Clinical Oncology Annual Meeting in Chicago and received an honorarium of \$500 plus conference fee, travel and accommodation expenses.

- He attended the ASCO Genito-Urinary Cancer Conference in February 2017, Orlando, Florida; the conference fee, travel and accommodation were paid by Bayer Health Care.
- He attended a trial investigator meeting in Berlin in June 2018 for a planned bladder cancer trial with rogaratinib. Accommodation and travel expenses were paid by Bayer Pharmaceuticals
- Private practice in the non-surgical management of breast and urological cancer (external beam radiotherapy and chemotherapy).

He further declared direct non-financial interests as follows:

- He is the principal investigator for the following ongoing commercially funded clinical trials in prostate cancer:
  - Radium-223 funded by Bayer Health Care
  - Rucaparib funded by Clovis Oncology
- He is the principal or co-investigator for the following ongoing non-commercially funded clinical trials in prostate cancer:
  - Stampede
  - The UK Genetic Prostate Cancer Study
  - Prompts
  - TOPARP
  - CTC Stop
- He is a member of the trial management group for the RT01 trial of external beam radiotherapy for prostate cancer.
- He is a member of the trial management group for the CHHIP trial of external beam radiotherapy for prostate cancer.

These interests were reviewed by the Programme Director and it was agreed that he could participate in the meeting.

The Committee proceeded to discuss the comments made during the second public consultation for the assessment of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10). All committee members had seen the full consultation comments submitted during the first and second consultations.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

## **End of Part 1**

**Part 2a – closed session**

Manufacturer representatives who had submitted additional confidential information were separately invited back into the meeting for further discussion with the committee.

The Chair thanked the manufacturer representatives and they left the meeting.

**Part 2b – closed session**

A decision on the content of the Diagnostics Guidance Document (DGD) was deferred pending additional analysis by the External Assessment Group (EAG).

**End of Part 2**

**Date, time and venue of next meeting**

**Tuesday 17 July 2018** at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD